Publication:
Cosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial.

cris.virtual.author-orcid0000-0003-4638-775X
cris.virtualsource.author-orciddcf039b3-51b9-457e-aa4f-439d935925b3
cris.virtualsource.author-orcid3137bca1-477f-4562-b565-bfea0295dddb
datacite.rightsopen.access
dc.contributor.authorBlum, Claudine Angela
dc.contributor.authorSchuetz, Philipp
dc.contributor.authorNigro, Nicole
dc.contributor.authorWinzeler, Bettina
dc.contributor.authorArici, Birsen
dc.contributor.authorRefardt, Julie
dc.contributor.authorUrwyler, Sandrine Andrea
dc.contributor.authorRodondi, Nicolas
dc.contributor.authorBlum, Manuel
dc.contributor.authorBriel, Matthias
dc.contributor.authorMueller, Beat
dc.contributor.authorChrist-Crain, Mirjam
dc.date.accessioned2024-10-07T16:45:41Z
dc.date.available2024-10-07T16:45:41Z
dc.date.issued2019-09
dc.description.abstractOBJECTIVE Glucocorticoids have been shown to improve outcome in community-acquired pneumonia (CAP). However, glucocorticoids have potential side-effects, and treatment response may vary. It is thus crucial to select patients with high likelihood to respond favorably. In critical illness, cosyntropin testing is recommended to identify patients in need for glucocorticoids. We investigated whether consyntropin testing predicts treatment response to glucocorticoids in CAP. DESIGN PREDEFINED SECONDARY ANALYSIS OF A RANDOMIZED CONTROLLED TRIAL: PATIENTS: HOSPITALIZED PATIENTS WITH CAP: MEASUREMENTS: We performed 1μg cosyntropin tests in a randomized trial comparing prednisone 50mg for seven days to placebo. We investigated whether subgroups based on baseline and stimulated cortisol levels responded differently to glucocorticoids with regards to time to clinical stability (TTCS) and other outcomes by inclusion of interaction terms into statistical models. RESULTS 326 patients in the prednisone and 309 patients in the placebo group were evaluated. Neither basal cortisol nor a Δcortisol<250nmol/L after stimulation nor the combination of basal cortisol and Δcortisol predicted treatment response as measured by TTCS (all p for interaction>0.05). Similarly, we found no effect modification with respect to mortality, rehospitalization, antibiotic treatment duration or CAP-related complications (all p for interaction>0.05). However, glucocorticoids had a stronger effect on shortening length of hospital stay in patients with a baseline cortisol of ≥938 nmol/L (p for interaction=0.015). CONCLUSIONS Neither baseline nor stimulated cortisol after low-dose cosyntropin testing at a dose of 1 μg predicted glucocorticoid responsiveness in mild to moderate CAP. A treatment decision for or against adjunct glucocorticoids in CAP should not be made depending on cortisol values or cosyntropin testing results. This article is protected by copyright. All rights reserved.
dc.description.numberOfPages9
dc.description.sponsorshipBerner Institut für Hausarztmedizin (BIHAM)
dc.description.sponsorshipUniversitätsklinik für Allgemeine Innere Medizin
dc.identifier.doi10.7892/boris.122332
dc.identifier.pmid30485501
dc.identifier.publisherDOI10.1111/cen.13907
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/61393
dc.language.isoen
dc.publisherBlackwell Scientific Publications
dc.relation.ispartofClinical endocrinology
dc.relation.issn0300-0664
dc.relation.organizationDCD5A442C058E17DE0405C82790C4DE2
dc.relation.organizationClinic of General Internal Medicine
dc.relation.organizationDCD5A442BDB9E17DE0405C82790C4DE2
dc.subjectACTH test Community-acquired Pneumonia Critical-Illness-related Corticosteroid Insufficiency adrenal function cosyntropin test glucocorticoids
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc300 - Social sciences, sociology & anthropology::360 - Social problems & social services
dc.titleCosyntropin testing does not predict response to glucocorticoids in community-acquired pneumonia in a randomized controlled trial.
dc.typearticle
dspace.entity.typePublication
dspace.file.typetext
dspace.file.typetext
oaire.citation.endPage382
oaire.citation.issue3
oaire.citation.startPage374
oaire.citation.volume91
oairecerif.author.affiliationBerner Institut für Hausarztmedizin (BIHAM)
oairecerif.author.affiliationUniversitätsklinik für Allgemeine Innere Medizin
oairecerif.author.affiliation2Clinic of General Internal Medicine
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.embargoChanged2019-11-29 01:30:35
unibe.date.licenseChanged2019-10-24 05:21:58
unibe.description.ispublishedpub
unibe.eprints.legacyId122332
unibe.journal.abbrevTitleCLIN ENDOCRINOL
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 2 of 2
Name:
Blum ClinEndocrinol 2018.pdf
Size:
593.51 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
accepted
Name:
Blum ClinEndocrinol(Oxf) 2019.pdf
Size:
379.38 KB
Format:
Adobe Portable Document Format
File Type:
text
License:
publisher
Content:
published

Collections